Cargando…

Serum Luteinizing Hormone Testing Can Identify Optimal Medical Castration

Detalles Bibliográficos
Autores principales:	Morote, Juan, Comas, Imma, Ferrer, Roser, Regis, Lucas, Celma, Anna, Santamaría, Anna, Planas, Jacques, Trilla, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Brief Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317878/ https://www.ncbi.nlm.nih.gov/pubmed/34337451 http://dx.doi.org/10.1016/j.euros.2020.06.002

Ejemplares similares

Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients
por: Morote, Juan, et al.
Publicado: (2017)

Definition of Castrate Resistant Prostate Cancer: New Insights
por: Morote, Juan, et al.
Publicado: (2022)

Methods for Evaluating the Efficacy of Medical Castration: A Systematic Review
por: Aguilar, Adriana, et al.
Publicado: (2023)

Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review
por: Triquell, Marina, et al.
Publicado: (2022)

Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category
por: Morote, Juan, et al.
Publicado: (2022)

The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
por: Campistol, Miriam, et al.
Publicado: (2022)

Multiparametric MRI for Staging of Prostate Cancer: A Multicentric Analysis of Predictive Factors to Improve Identification of Extracapsular Extension before Radical Prostatectomy
por: Triquell, Marina, et al.
Publicado: (2022)

Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review
por: Cuadras, Mercè, et al.
Publicado: (2022)

Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand
por: Morote, Juan, et al.
Publicado: (2022)

Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy
por: Morote, Juan, et al.
Publicado: (2022)

The Barcelona Predictive Model of Clinically Significant Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study
por: Angulo, J. C., et al.
Publicado: (2022)

Comment on “Hypogonadotrophic hypogonadism due to a mutation in the luteinizing hormone β-subunit gene”
por: Valdes-Socin, Hernan, et al.
Publicado: (2017)

Bladder Cancer in an Inguinoscrotal Vesical Hernia
por: Regis, Lucas, et al.
Publicado: (2012)

Response to comment on “Hypogonadotrophic hypogonadism due to a mutation in the luteinizing hormone β-subunit gene”
por: Ihm, Sung-Hee
Publicado: (2017)

The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer
por: Milecki, Tomasz, et al.
Publicado: (2014)

Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness
por: Morote, Juan, et al.
Publicado: (2014)

AR and PI3K Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer
por: Vanwelkenhuyzen, Jan, et al.
Publicado: (2023)

Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer
por: Koh, Yoko, et al.
Publicado: (2020)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
por: Markowski, Mark C., et al.
Publicado: (2022)

Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome
por: Liu, Nana, et al.
Publicado: (2012)

Characterization of Luteinizing Hormone and Luteinizing Hormone Receptor and Their Indispensable Role in the Ovulatory Process of the Medaka
por: Ogiwara, Katsueki, et al.
Publicado: (2013)

Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl)
por: van Rossum, Huub H., et al.
Publicado: (2023)

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
por: Shim, Myungsun, et al.
Publicado: (2019)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [(177)Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
por: Stangl-Kremser, Judith, et al.
Publicado: (2021)

Castration for Crime Not Justifiable nor Effective
por: DeCausey,
Publicado: (1896)

Oligometastasis in Prostate Cancer: Can We Learn from Those “Excluded” from a Phase 2 Trial?
por: Glicksman, Rachel M., et al.
Publicado: (2023)

Response of the corpus luteum to luteinizing hormone.
por: Niswender, G D
Publicado: (1981)

Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome
por: Chun, Sungwook
Publicado: (2014)

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2023)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells
por: Cánovas, Verónica, et al.
Publicado: (2017)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
por: Zaitsu, Masayoshi, et al.
Publicado: (2012)

Nuclear and cytosolic pS727-STAT3 levels correlate with overall survival of patients affected by clear cell renal cell carcinoma (ccRCC)
por: Arévalo, Jazmine, et al.
Publicado: (2021)

SAT-LB1 Detection of Serum Macro-Luteinizing Hormone
por: Ogura-Ochi, Kanako, et al.
Publicado: (2020)

Luteinizing hormone and its dilemma in ovulation induction
por: Kumar, Pratap, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9gv5oo8s2l4nftp37n2pa9gd31